Cargando…

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED

Detalles Bibliográficos
Autores principales:	Lucijanic, Marko, Krecak, Ivan, Soric, Ena, Sabljic, Anica, Galusic, Davor, Holik, Hrvoje, Perisa, Vlatka, Perić, Martina Morić, Zekanovic, Ivan, Kušec, Rajko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429213/ http://dx.doi.org/10.1097/01.HS9.0000975624.80756.cf

Ejemplares similares

Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2201: ASSOCIATION OF HIGH PLATELETCRIT WITH THROMBOTIC RISK IN POLYCYTHEMIA VERA DEPENDS ON HEMATOCRIT AND LEUKOCYTE COUNT
por: Krecak, Ivan, et al.
Publicado: (2023)

P1039: PALPABLE SPLEEN SIZE IS PROGNOSTIC IN PRIMARY BUT NOT SECONDARY MYELOFIBROSIS
por: Lucijanic, M., et al.
Publicado: (2022)

P1040: HIGHER ESTIMATED PLASMA VOLUME STATUS IS ASSOCIATED WITH INCREASED THROMBOTIC RISK AND IMPAIRED SURVIVAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Lucijanic, M., et al.
Publicado: (2022)

P1051: CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

PB2194: HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2188: PROTON PUMP INHIBITORS ARE SAFE AND EFFECTIVE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA TREATED WITH LOW-DOSE ASPIRIN
por: Krecak, Ivan, et al.
Publicado: (2023)

Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
por: Lucijanic, Marko, et al.
Publicado: (2021)

PB1825: TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF ACUTE MYELOID LEUKEMIA PATIENTS MANAGED IN THE COMMUNITY SETTING IN CROATIA
por: Krecak, I., et al.
Publicado: (2022)

Comparison of IMPROVE, modified IMPROVE, IMPROVEDD, Padua and CHA2DS2-VASC risk scores for venous and arterial thrombotic events prediction in hospitalized COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2022)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

PB2219: POLYPHARMACY AND DRUG-TO-DRUG INTERACTIONS MAY HAVE A NEGATIVE EFFECT ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

PB2018: MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM RELAPSE IN THE ERA OF NOVEL DRUGS - A MULTICENTER RETROSPECTIVE STUDY FROM THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGICAL MALIGNANCIES (KROHEM)
por: Mitrovic, Z., et al.
Publicado: (2022)

PB2220: MORTALITY IN PATIENTS WITH HEMOGLOBINOPATHIES AND (SARS-COV-2) COVID-19 INFECTION: SAUDI ARABIA EXPERIENCE
por: Ezzat, H., et al.
Publicado: (2022)

P1691: COMPARISON OF IMPROVE, MODIFIED IMPROVE, IMPROVEDD AND PADUA RISK SCORES FOR VENOUS THROMBOEMBOLISM PREDICTION IN HOSPITALIZED COVID-19 PATIENTS
por: Lucijanic, M., et al.
Publicado: (2022)

Ruxolitinib withdrawal due to the COVID-19
por: Lucijanic, Marko, et al.
Publicado: (2021)

Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study
por: Holik, Hrvoje, et al.
Publicado: (2023)

PB2269: HUMORAL AND T-CELL RESPONSES TO SARS-COV2 VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA MANAGED IN THE COMMUNITY SETTING
por: Holik, H., et al.
Publicado: (2022)

Duffy‐null erythrocyte phenotype and the risk of thrombotic events in essential thrombocythemia
por: Krecak, Ivan, et al.
Publicado: (2023)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases
por: Aurer, Igor, et al.
Publicado: (2021)

PB2350: SAFETY AND EFFICACY OF HYPODERMOCLYSIS IN PATIENTS WITH HEMATOLOGICAL CANCERS
por: Kodru, A., et al.
Publicado: (2022)

A detector to study xi(2220) at LEAR
por: Buzzo, A, et al.
Publicado: (1984)

Memorandum: possible measurement of the $\xi(2220)$ at LEAR
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1984)

PReS-FINAL-2220: Cochlear involvement in FMF
por: Keskindemirci, G, et al.
Publicado: (2013)

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY
por: Huang, J., et al.
Publicado: (2022)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?
por: Cuadrado, Isabel Montero
Publicado: (2023)

PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE
por: Riazat-Kesh, Yosef Joseph Rene Amel, et al.
Publicado: (2023)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
por: Montero, M. I.
Publicado: (2022)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
por: Chen, C., et al.
Publicado: (2022)

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS
por: Junker, Sophia, et al.
Publicado: (2023)

PB2055: A RARE CASE OF HIGH-RISK HEREDITARY THROMBOPHILIA COMBINED WITH PRIMARY MYELOFIBROSIS
por: Khoduleva, S., et al.
Publicado: (2022)

PB2166: PRIMARY MYELOFIBROSIS: SERUM LACTATE DEHYDROGENASE AS A PREDICTOR OF EARLY LEUKEMIC PROGRESSION
por: Moura, Pedro, et al.
Publicado: (2023)

PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
por: Kaynak, Emine, et al.
Publicado: (2023)

Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms
por: Krečak, Ivan, et al.
Publicado: (2023)

More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
por: Lucijanic, Marko, et al.
Publicado: (2021)

Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
por: Sertić, Zrinka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l3m7pqnbnsqnujndf6916p8r8s